Dow and lawyers reach agreement on implant suits
Article Abstract:
An end was reached to one of American corporate history's most controversial lawsuits when lawyers for Dow Corning Corp. and women claiming injury from silicone breast implant surgery tentatively agreed to a $3.2 billion settlement. The agreement not only would protect Dow Corning from future liability claims relating to silicone breast implants, but it would allow the company to emerge from Chapter 11 bankruptcy protection. The agreement still must be approved by 2/3 of the 170,000 women who have filed claims against the company, Dow Corning's creditors and the company's bankruptcy judge.
Comment:
Tentative $3.2 bil settlement reached in long-standing lawsuit by women who cliamed injury from silcone breast implants
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
United Healthcare takes a $900 million charge
Article Abstract:
United Healthcare Corp. has announced that it will take a $900 million charge in its second quarter following its decision to abandon unprofitable Medicare plans. Industry analysts, who are questioning whether HMOs will be able to turn a profit on Medicare in the future, believe that the company's move may jeopardize its proposed $5.5 billion merger with Humana Inc. United Healthcare, which said that its other operations remain profitable, wasn't able to reassure investors, who rushed to abandon health care stocks.
Comment:
Announces that it will take a $900 mil charge in second quarter, following decision to abandon unprofitable Medicare plans
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Lilly to stop developing migraine drug
Article Abstract:
The migraine drug that Eli Lilly & Co. has been developing along with Synaptic Pharmaceutical Corp. will be abandoned because of toxicity seen in animal studies. The two say they will look for other uses for the drug. Lilly has other drugs in its pipeline that show promise; Actos for diabetes is one, a drug made by Japanese firm, Takeda Chemical Industries. Lilly will market Actos in the U.S.
Comment:
Lilly will work with Synaptic Pharmaceuticals to find other uses for the drug
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: An HMO chief makes a bet on being big. United HealthCare takes a big charge. United HealthCare to acquire Humana: plan to form U.S.'s biggest managed-care concern is valued at $5.38 billion
- Abstracts: Scotts agrees to buy part of Monsanto unit in a $300 million deal. American Home, Monsanto to combine in a stock swap valued at $35.08 billion
- Abstracts: Duke tests nuclear agency on renewing plant license. The nuclear power elite; a small circle of companies seeks control of reactors
- Abstracts: Keeping Walgreens on Main St. Lazard to pay $9 million in yield-burning suit. Some clouds dim a star of on-line trading
- Abstracts: London and Frankfurt stock exchanges form alliance. Deutsche gets Bankers Trust for $10 billion. Siemens to sell big units in bid to shore up profitability